Cancer Research Landon Prizes for Basic and Translational Cancer Research Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
[Cancer Research 59, 6033-6037, December 1, 1999]
© 1999 American Association for Cancer Research
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lew, Y. S.
Right arrow Articles by Kim, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lew, Y. S.
Right arrow Articles by Kim, J. H.
[Cancer Research 59, 6033-6037, December 15, 1999]
© 1999 American Association for Cancer Research

Advances in Brief

Arsenic Trioxide Causes Selective Necrosis in Solid Murine Tumors by Vascular Shutdown1

Young S. Lew2, Stephen L. Brown, Robert J. Griffin, Chang W. Song and Jae Ho Kim

Department of Radiation Oncology, Henry Ford Health System, Detroit, Michigan 48202 [Y. S. L., S. L. B., J. H. K.] and Department of Therapeutic Radiology-Radiation Oncology, University of Minnesota Medical School, Minneapolis, Minnesota 55455 [R. J. G., C. W. S.]

To investigate the antitumor action of arsenic trioxide in solid tumors, we carried out quantitative tumor perfusion studies, using locally advanced methylcholanthrene-induced fibrosarcoma grown in BALB/c mice. The tumor perfusion studies were assessed by two separate methods: 99mTc clearance and 86Rb uptake. A single administration of arsenic trioxide (10 mg/kg i.p.) produced a preferential vascular shutdown in the tumor tissue at 2 and 6 h, leading to massive necrosis in the central part of the tumor. The phenomenon was repeatable at intervals of weekly administration of the drug in the same tumor. Normal skin, muscle, and kidney were relatively unaffected by arsenic trioxide. These results suggest that the drug may be investigated as an adjunct to the standard cancer therapeutic modalities.




This article has been cited by other articles:


Home page
 Molecular Cancer TherapeuticsHome page
P. Kumar, Q. Gao, Y. Ning, Z. Wang, P. H. Krebsbach, and P. J. Polverini
Arsenic trioxide enhances the therapeutic efficacy of radiation treatment of oral squamous carcinoma while protecting bone
Mol. Cancer Ther., July 1, 2008; 7(7): 2060 - 2069.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. R. Horsman and D. W. Siemann
Pathophysiologic Effects of Vascular-Targeting Agents and the Implications for Combination with Conventional Therapies
Cancer Res., December 15, 2006; 66(24): 11520 - 11539.
[Abstract] [Full Text] [PDF]

Home page
 RadiologyHome page
A. Hines-Peralta, V. Sukhatme, M. Regan, S. Signoretti, Z.-j. Liu, and S. N. Goldberg
Improved Tumor Destruction with Arsenic Trioxide and Radiofrequency Ablation in Three Animal Models
Radiology, July 1, 2006; 240(1): 82 - 89.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. Douer and M. S. Tallman
Arsenic Trioxide: New Clinical Experience With an Old Medication in Hematologic Malignancies
J. Clin. Oncol., April 1, 2005; 23(10): 2396 - 2410.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
N. V. Soucy, M. A. Ihnat, C. D. Kamat, L. Hess, M. J. Post, L. R. Klei, C. Clark, and A. Barchowsky
Arsenic Stimulates Angiogenesis and Tumorigenesis In Vivo
Toxicol. Sci., December 1, 2003; 76(2): 271 - 279.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Radiol.Home page
G M Tozer
Measuring tumour vascular response to antivascular and antiangiogenic drugs
Br. J. Radiol., December 1, 2003; 76(suppl_1): S23 - S35.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
Y. S. Lew, A. Kolozsvary, S. L. Brown, and J. H. Kim
Synergistic Interaction with Arsenic Trioxide and Fractionated Radiation in Locally Advanced Murine Tumor
Cancer Res., August 1, 2002; 62(15): 4202 - 4205.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. H. Miller Jr., H. M. Schipper, J. S. Lee, J. Singer, and S. Waxman
Mechanisms of Action of Arsenic Trioxide
Cancer Res., July 15, 2002; 62(14): 3893 - 3903.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
M. A. Hussein
Nontraditional Cytotoxic Therapies for Relapsed/Refractory Multiple Myeloma
Oncologist, April 1, 2002; 7(90001): 20 - 29.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. Maeda, S. Hori, H. Nishitoh, H. Ichijo, O. Ogawa, Y. Kakehi, and A. Kakizuka
Tumor Growth Inhibition by Arsenic Trioxide (As2O3) in the Orthotopic Metastasis Model of Androgen-independent Prostate Cancer
Cancer Res., July 1, 2001; 61(14): 5432 - 5440.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
S. Waxman and K. C. Anderson
History of the Development of Arsenic Derivatives in Cancer Therapy
Oncologist, April 1, 2001; 6(90002): 3 - 10.
[Abstract] [Full Text]

Home page
 ASH Education BookHome page
R. J. Klasa, A. F. List, and B. D. Cheson
Rational Approaches to Design of Therapeutics Targeting Molecular Markers
Hematology, January 1, 2001; 2001(1): 443 - 462.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1999 by the American Association for Cancer Research.